Neurol. praxi. 2014;15(2):68-70

Some biological and biochemical markers of multiple sclerosis

MUDr. Jozef Michalik1, MUDr. Daniel Čierny2, prof. RNDr. Ján Lehotský, DrSc.2, prof. MUDr. Egon Kurča, PhD.1
1 Neurologická klinika Jesseniovej LF UK a Univerzitnej nemocnice Martin
2 Ústav lekárskej biochémie Jesseniovej LF UK, Martin

This paper discusses the potential applicability of some biological markers (genetic markers, Epstein-Barr virus nuclear antigen 1 antibody, vitamin D) for the diagnosis, disease activity, prediction of clinical courses and response to disease modifying therapies.

Keywords: multiple sclerosis, demyelination, genetics, vitamin D, Epstein-Barr virus antibody, apolipoprotein E

Published: May 10, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Michalik J, Čierny D, Lehotský J, Kurča E. Some biological and biochemical markers of multiple sclerosis. Neurol. praxi. 2014;15(2):68-70.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alotaibi S. Epstein-Barr virus in pediatric multiple sclerosis. J Am Med Assoc. 2004: 1875-1879. Go to original source... Go to PubMed...
    2. Barcellos LF, Sawcer S, Ramsay PP, Baranzini SE, Thomson G, Briggs F, Cree BC, Begovich AB, Villoslada P, Montalban X, Uccelli A, Savettieri G, Lincoln RR, DeLoa C, Haines JL, Pericak-Vance MA, Compston A, Hauser SL, Oksenberg JR. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum Mol Genet. 2006; 15: 2813-2824. Go to original source... Go to PubMed...
    3. Bieleková B, Martin R. Development of biomarkers in multiple sclerosis. Brain. 2004; 127(7): 1463-1478. Go to original source... Go to PubMed...
    4. Bischoff-Ferrari HA, Giovannuci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006; 84(1): 18-28. Go to original source... Go to PubMed...
    5. Buck D, Cepok S, Hoffmann S, Jochim A, Berthele A, Hartung HP, Wassmuth R, Hemmer B. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol. 2011; 68(4): 480-487. Go to original source... Go to PubMed...
    6. Comabella M, Craig DW, Morcillo-Suarez C, Rio J, Navarro A, Fernandez M, Martin R, Montalban X. Genome-wide scan of 500,000 single-nucleotide polymorphisms among responders and nonresponders to interferon beta therapy in multiple sclerosis. Arch Neurol. 2009; 66:72-978. Go to original source... Go to PubMed...
    7. Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009; 132(5): 1146-1160. Go to original source... Go to PubMed...
    8. D'Netto MJ, Ward H, Morrison KM, Ramagopalan SV, Dyment DA, DeLuca GC, Handunnetthi L, Sadovnick AD, Ebers GC. Risk alleles for multiple sclerosis in multiplex families. Neurology. 2009; 72(23): 1984-1988. Go to original source... Go to PubMed...
    9. DeLuca GC, Ramagopalan SV, Herrera BM, Dyment DA, Lincoln MR, Montpetit A, Pugliatti M, Barnardo MCN, Risch NJ, Sadovnick AD, Chao M, Sotgiu S, Hudson TJ, Ebers GC. An extremes of outcome strategy provides evidence that multiple sclerosis severity is determined by alleles at the HLA-DRB1 locus. Proc Nat Acad Sci. 2007; 104: 20896-20901. Go to original source... Go to PubMed...
    10. Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Hamada T, Miysaka K, Tashiro K. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci. 1999; 166(1): 47-52. Go to original source... Go to PubMed...
    11. Ghaffar O, Reis M, Pennell N, O'Connor P, Feinstein A. APOE epsilon-4 and the cognitive genetics of multiple sclerosis. Neurology. 2010; 74: 1611-1618. Go to original source... Go to PubMed...
    12. Chapman J, Vinokurov S, Achiron A, Karussis DM, Mitosek-Szewczyk K, Birnbaum M, Michaelson DM, Korczyn AD. APOE genotype is a major predictor of long-term progression of disability in MS. Neurology. 2001; 56(3): 312-316. Go to original source... Go to PubMed...
    13. Lesko LJ, Atkinson AJ. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol. 2001; 41: 347-366. Go to original source... Go to PubMed...
    14. Link J, Kockum I, Lorentzen AR, Lie BA, Celius EG, Westerlind H, Schaffer M, Alfredson L, Olsson T, Brynedal B, Harbo HF, Hillert J. Importance of human leukocyte antigen (HLA) class I and II alleles on the risk of multiple sclerosis. PLoS ONE. 2012; 7(5): e36779. Go to original source... Go to PubMed...
    15. Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H, Caballero E, Münz C, Montalban X, Comabella M. Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol. 2010; 67(2): 159-169. Go to original source... Go to PubMed...
    16. Marrosu MG, Murru MR, Costa G, Murru R, Muntoni F, Cucca F. DRB1-DQA1-DQB1 loci and multiple sclerosis predisposition in the Sardinian population. Hum Mol Genet. 1998; 7: 1235-1237. Go to original source... Go to PubMed...
    17. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006; 296(23): 2832-2838. Go to original source... Go to PubMed...
    18. Pohl D, Krone B, Rostasy K, Hahler E, Brunner E, Lehnert M, Wagner HJ, Gartner J, Hanefeld F. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology. 2006; 67(11): 2063-2065. Go to original source... Go to PubMed...
    19. Santiago O, Gutierrez J, Sorlozano A, de Dios Luna E, Villegas E, Fernandez O. Relation between Epstein-Barr virus and multiple sclerosis: analytic study of scientific production. Eur J Clin Microbiol Infect Dis. 2010; 29(7): 857-866. Go to original source... Go to PubMed...
    20. Simon KC, Munger KL, Yang X, Ascherio A. Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Multiple Sclerosis. 2010; 16(2): 133-138. Go to original source... Go to PubMed...
    21. Simon KC, Munger KL, Kraft P, Hunter DJ, De Jager PL, Ascherio A. Genetic predictors of 25-hydroxyvitamin D levels and risk of multiple sclerosis. J Neurol. 2011; 258(9): 1676-1682. Go to original source... Go to PubMed...
    22. Stewart N, Simpson S Jr, van der Mei I, Ponsonby AL, Blizzard L, Dwyer T, Pittas F, Eyles D, Ko P, Taylor BV. Interferon-? and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology. 2012; 79(3): 254-260. Go to original source... Go to PubMed...
    23. Sundqvist E, Baarnhielm M, Alfreddson L, Hillert J, Olsson T, Kockum I. Confirmation of association between Multiple Sclerosis and CYP27B1. Eur J Hum Gen. 2010; 18(12): 1349-1352. Go to original source... Go to PubMed...
    24. Tajouri L, Ovcaric M, Curtain R, Johnson MP, Griffiths LR, Csurhes P, Pender MP, Lea RA. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J Neurogenet. 2005; 19(1): 25-38. Go to original source... Go to PubMed...
    25. Wang JH, Pappas D, de Jager PL, Pelletier D, de Bakker PI, Kappos L, Polman CH, Chibnik LB, Hafler DA, Matthews PM. Australian and New Zealand Multiple Sclerosis Genetics Consortium (ANZgene), Chibnik LB, Hafler DA, Matthews PM, Hauser SL, Baranzini SE, Oksenberg JR. Modeling the cumulative genetic risk for multiple sclerosis from genome-wide association data. Genome Med. 2011; 3(1): 3. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.